Eam Investors, LLC Tricida, Inc. Transaction History

Eam Investors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $159,034 - $254,156	-18,688 Reduced 19.15%	78,880 $827,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $713,222 - $1.16 Million	97,568 New	97,568 $944,000
Q3 2019 Nov 13, 2019	SELL	$29.87 - $42.22 $953,868 - $1.35 Million	-31,934 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$31.16 - $39.46 $91,641 - $116,051	-2,941 Reduced 8.43%	31,934 $1.26 Million
Q1 2019 May 13, 2019	BUY	$19.96 - $38.62 $696,105 - $1.35 Million	34,875 New	34,875 $1.35 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.